OncoMatch/Clinical Trials/NCT06196255
Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
Is NCT06196255 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies anti-FcRL5 CAR-T for multiple myeloma.
Treatment: anti-FcRL5 CAR-T — This is an open label, single-arm, Phase 2 study to evaluate the efficacy and safety of Anti-FcRL5 CAR-T in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture. Anti-FcRL5 chimeric antigen receptor (CAR) modified T cells. Prior to Anti-FcRL5 infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Lab requirements
Kidney function
no serious kidney disease
Liver function
ALT and AST <3 times normal; bilirubin <2.0mg / dl
Cardiac function
no serious heart disease
ALT and AST <3 times normal; bilirubin <2.0mg / dl; The patient has no serious heart, liver, kidney and other diseases
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify